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Postoperative ventilationAbstract Background: Simple surgical procedures in pediatric open cardiac surgery can be
planned for early extubation by using dexmedetomidine alpha2 agonist. Early extubation is associ-
ated with shortening of postoperative ventilation and intensive care unit length of stay. The aim of
this study was to examine the effects of dexmedetomidine on recovery proﬁle, ICU length of stay,
analgesic needs, and hospital stay in pediatric patients undergoing elective correction of congenital
heart diseases using CPB.
Methods: Forty patients with age ranging from 2–10 years of either sex submitted for elective cor-
rection of simple congenital heart diseases undergoing CPB. All patients were premedicated in pre-
operative area with intramuscular 0.1 mg/kg midazolam and 0.015 mg/kg atropine sulfate. Patients
were randomly classiﬁed into one of two equal groups (n= 20). In the Dex group, patients received
an initial bolus dose of dexmedetomidine (0.4 lg/kg) over 10 min, followed by continuous infusion
of 0.5 lg/kg/hr. In the control group, patients received an initial bolus dose of saline over 10 min,
followed by continuous infusion of 0.5 lg/kg/hr.
Results: MAP, HR, the total dose of intra-operative fentanyl, vasodilator needs, time of extuba-
tion, pain score, ICU length of stay and hospital stay were signiﬁcantly higher in the control group
when compared with DEX group. Also in control group these were signiﬁcant decrease in HR and
MAP relative to baseline. There was signiﬁcant increase in duration of inotropic support in control
group than DEX group.
Conclusion: Dexmedetomidine is a short-acting alpha2-adrenoceptor agonist with many desirable
clinical beneﬁts that encourage its use in the perioperative period. Dexmedetomidine has anesthesia-
sparing effects, it decreases MAP, HR and with reasonable analgesic effect.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.D license.1. Introduction
Fast tracking in cardiac surgery refers to the concept of early
extubation, mobilization and hospital discharge in an effort
to reduce costs and perioperative morbidity [1].
Early extubation after pediatric open cardiac surgery is still
not common practice. Several more recent studies describing
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such as atrial septal defects procedures not requiring CPB, and
relatively low risk patients, very early extubation refers to
planned extubation either in the operating room or immedi-
ately upon arrival in the intensive care unit [2].
Shortening of both postoperative ventilation and intensive
care unit (ICU) length of stay are important goals to avoid
complications related to mechanical ventilation, to improve
patient outcome, and to reduce costs of ICU treatment [3].
Dexmedetomidine is a highly speciﬁc, selective alpha2 adre-
noceptor agonist [4]. It has activity at the imidazoline receptors
involved in central blood pressure control also causes reduc-
tion in sympathetic nervous system activity [5]. With dexmede-
tomidine, there are a number of reasons for the growing and
renewed interest in the use of alpha2-adrenoceptors agonists
as sedatives: dexmedetomidine compared to clonidine is a
much more selective alpha2-adrenoceptor agonist. In addition,
dexmedetomidine is shorter-acting drug than clonidine and has
a reversal drug for its sedative effect, Atipamezole. These prop-
erties render dexmedetomidine suitable for sedation and anal-
gesia during the whole perioperative period [6].
To our knowledge it is the ﬁrst study to examine the effects
of dexmedetomidine on recovery proﬁle, ICU length of stay
and hospital stay in pediatric patients undergoing corrective
surgery for congenital heart diseases using CPB.2. Patients and methods
After approval of the local ethics committee of Anesthesia and
Surgical Intensive Care Department, Faculty of Medicine,
Mansoura University Children Hospital and obtained written
informed consent from the parents of all patients, 40 patients
with age ranging from 2 to 10 years of either sex submitted
for elective correction of simple congenital heart diseases
undergoing CPB at Mansoura University children hospital.
From January 2012 to August 2012 patients of redo open heart
surgery, endocarditis, neurological diseases, renal diseases,
hepatic diseases, pulmonary diseases, heart failure and moder-
ate to severe pulmonary hypertension and previous adverse
reaction to any of the study medication were excluded from
the study. All patients were premedicated in preoperative area
with intramuscular 0.1 mg/kg midazolam and 0.015 mg/kg
atropine sulfate before induction of general anesthesia. ECG,
peripheral oxygen saturation and noninvasive blood pressure
were monitored. Supplemental O2 was provided via a face
mask.
In both groups anesthesia was induced by inhalation of
sevoﬂurane carried by oxygen, with loss of consciousness a
peripheral intravenous indwelling cannula was inserted, then
fentanyl (3–5 lg/kg) was given, tracheal intubation and neuro-
muscular blockade were facilitated by rocuronium 0.9 mg/kg,
positive pressure ventilation was applied via face mask at a
rate of 20–28 breath per minute. Patients were mechanically
ventilated with 50% O2 in air and the end tidal CO2 was mon-
itored by side-stream capnogragh and maintained between 30
and 35 mmHg, then central venous and an arterial catheter
were inserted and entropy module was attached to the patient’s
forehead. Anesthesia was maintained with sevoﬂurane titrated
to keep the entropy value around 50, increment doses of fenta-
nyl were given to maintain heart rate and blood pressure
within 20% of the basal value with maximum total dose of10 l/kg and constant infusion of esmeron (0.3 mg/kg/hr) to
maintain muscle relaxation. Neuromuscular blockade was
reversed at the end of surgery if the patient was valuable for
extubation. All patients received ringer’s acetate solution
4 ml/kg/hr for ﬁrst 10 kg, 2 ml/kg/hr for next 10 kg, 1 ml/kg/
hr for each kg. Patients were randomly classiﬁed into one of
two equal groups (n= 20). In the Dex group, patients received
an initial bolus dose of dexmedetomidine (0.4 lg/kg) over
10 min immediately after induction, followed by continuous
infusion of 0.5 lg/kg/hr. All over the operation and was dis-
continued at the end of CPB. A similar volume of normal sal-
ine was given in the control group.
Hemodynamic variables HR and MAP were recorded at
baseline, after induction, after skin incision, post sternotomy,
20 min post CPB and after closure of sternum.
Operative parameters as total dose of fentanyl, aortic cross
clamping time (min), CPB time, duration of surgery (min),
needs of DC shocks, duration of inotropic support and total
dose of vasodilator needs were recorded in all patients.
ICU parameters as time of extubation, pain score by objec-
tive pain discomfort score (blood pressure, crying, moving, agi-
tation, verbal), ICU length of stay, and hospital length of stay.
In all patients, the heart was approached through a stan-
dard median sternotomy. The ascending aorta, SVC and
IVC were cannulated for cardiopulmonary bypass (Stockert
instrument, Germany) using a membrane oxygenator and a
nonpulsatile roller pump ﬂow with average rate around 100–
150 ml/kg/min. with an arterial ﬁlter after elevation of the
ACT above 480 s using heparin (300–400 i.u/kg). Moderate
hypothermia (32 c) was allowed, after aortic cross clamping,
all patients received custodial cardioplegia (50 ml/kg).
Hematocrit was maintained between 20% and 25% during
CPB, with addition of blood as necessary and anesthesia was
maintained by propofol infusion 100–150 lg/kg/min after
adding of 3 mg/kg to CPB prime. Nitroglycerin infusion was
initiated during the rewarming period, to keep MAP around
50 mmHg.
2.1. Sample size calculation
Sample size was done, based on extubation time. We expect to
have a difference of 1.5 between the two groups. Using the t
test for comparison and setting alpha to 0.05, we need mini-
mally 21 cases in each arm to detect a similar difference with
80% power. We increase the sample to 30 cases in each arm.
Calculations were done using medcalc software Windows.
Data were ﬁrst tested for normality by Klomogorov–Smir-
nov test. Normally distributed continuous data were analyzed
by using student t-test. Non-normally distributed continuous
and ordinal data were analyzed using Mann-Whitey U test.
Categorical data were analyzed by Chi-square or Fisher’s exact
test as appropriate. The results are presented as mean (SD),
median (interquartile range), or number of patients as appro-
priate. A P value <0.05 was considered statistically signiﬁcant.
Statistical analyses were performed using the SPSS for Win-
dows, version 18.
3. Results
Table 1 shows the patients characteristics of the studied
groups, control group (n= 20), and DEX group (n= 20),
Table 1 Demographic data of the studied groups: control
group (n= 30); DEX group (n= 30); data are in number,
mean ± SD.
Control group DEX group P value
Age (years) 4.75 ± 3.18 4.42 ± 3.09 0.49
Weight (kilogram) 18.6 ± 8.8 17.7 ± 8.2 0.63
Sex M/F 11/19 12/18 0.99
Surgical procedures 0.79
ASD repair 12 16
VSD repair 18 14
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regards, age, weight, height, M/F ratio and the type of surgical
procedure.
In the present study, MAP and HR were signiﬁcantly high
in the control group when compared with DEX group post
induction and throughout the surgery. Also HR and MAP
were signiﬁcantly high in control group relative to its baseline
values (Figs. 1 and 2 respectively).
There was signiﬁcant increase in total dose of intra-opera-
tive fentanyl, pain score, duration of inotropic support, vaso-
dilator needs, time of extubation, ICU length of stay and
hospital stay together with high readings of entropy values in
control group than DEX group (Tables 2–4 and Fig. 3
respectively).
There was no signiﬁcant difference between the two groups
as regard aortic cross clamp time, CPB time, duration of
surgery, need of DC shocks for deﬁbrillation (Table 2).
4. Discussion
Dexmedetomidine is a selective a2-adrenoceptor agonist.
Its action is different according to the site of receptors.
Alpha2-adrenoceptors are found in peripheral and central ner-
vous systems, in effector organs such as the liver, kidney, pan-
creas, eye vascular smooth muscles and platelets [7].
In the present study, we noted that patients who received
dexmedetomidine showed signiﬁcant decrease in HR, MAP,Figure 1 Heart rate (HR) changes, (beat/minute) in the studied grou
 P< 0.001 signiﬁcant when compared with the basal value.pain score, fentanyl requirements, entropy values, ICU length
of stay and hospital stay when compared to control group.
A biphasic cardiovascular response has been described after
the administration of dexmedetomidine. A bolus of 1 lg/kg
results in a transient increase in blood pressure and a reﬂex
decrease in heart rate. This initial response is attributed to
the direct effects of alpha2 B-adrenoceptor stimulation of vas-
cular smooth muscle. This response can be attenuated by a
slow infusion over 10 min, but even at slower infusion rates,
the transient increase in mean BP and the decrease in HR over
the ﬁrst 10 min are shown. This initial response is followed by
a decrease in BP. Both these effects are presumably caused by
an inhibition of central sympathetic outﬂow that overrides the
direct effects of dexmedetomidine on the vasculature [8].
In our study there is a signiﬁcant decrease in HR and MAP
in dexmedetomidine group when compared to control group.
The reduction in MAP may be attributed to decreasing sympa-
thetic outﬂow and circulating catecholamines by dexmedetom-
idine [9]. Also dexmedetomidine has been associated with
decrease in HR, in part because of sympatholytic effects of this
drug, but also because of a vagal mimetic effect [10].
These effects match with monophasic effect of dexmede-
tomidine (low dose of 0.25–0.5 lg/kg resulted in a monophasic
decrease in MAP) as we used a dose less than 1 lg/kg, which
also explain the lower needs of vasodilators in DEX group
than control group [11]. Our ﬁndings are supported by previ-
ous studies done by Talk, and Ebert who proved that the
use of dexmedetomidine associate with biphasic effect of
dexmedetomidine in large dose and monophasic effect in small
dose [12,13].
Another important ﬁnding in this study is the signiﬁcant
reduction in the total dose of intraoperative fentanyl and pain
score in DEX group relatively to control group, this is in
accordance with Venn et al. that showed a reduction in opioids
requirements of 50% in twenty adult ICU patients [14]. Also
this was conﬁrmed by Martin’s study of 401 post-surgical
patients [15].
It is known that dexmedetomidine decreases noradrenergic
output from the locus cereleus allowing for increased ﬁring of
inhibitory neurons including GABA. Primary analgesic effects
and potentiation of opioid-induced analgesia result from theps. * P< 0.001signiﬁcant when compared with the control group.
Figure 2 Mean arterial pressure changes (MAP), (mm Hg) in the studied groups. *** P< 0.001 signiﬁcant when compared with the
control group.
Table 2 Intraoperative data: (total dose of fentanyl (lg/kg), cardiopulmonary bypass time (min), aortic cross clamp time (min),
duration of surgery (min), total dose of nitroglycerin (lg/kg/min)). Control group (n= 30); DEX group (n= 30); data are in number,
mean ± SD.
Control group DEX group P value
Total dose of fentanyl (lg) 160 ± 12 145 ± 9* <0.001***
Aortic cross clamp time (min) 29.9 ± 9.1 28.7 ± 11.5 0.65
Cardiopulmonary bypass time (min) 46.2 ± 10.4 45.1 ± 12 0.73
Duration of surgery (min) 136.2 ± 15 134.1 ± 19 0.64
Need for DC shock 2 1 0.92
Duration of intropic support (hr) 13.1 ± 2.3 9.6 ± 1.59* <0.001***
Total dose of nitroglycerine dose (lg) 185 ± 9 153 ± 8* <0.001***
* P < 0.05 signiﬁcant when compared with the basal value.
*** P< 0.001 signiﬁcant when compared with the control group.
Table 3 Postoperative data: Extubation time (hr), ICU length of stay (hr), hospital length of stay (days). Control group (n= 30);
DEX group (n= 30); data are in mean ± SD.
Control group DEX group P value
Extubation time (hr) 5 ± 1.22 2.1 ± 0.8 <0.001***
ICU length of stay (hr) 34.3 ± 12.1 26.7 ± 7.8 <0.001***
Hospital length of stay (days) 6.1 ± 1.0 4.2 ± 0.8* 0.002**
* P< 0.05 signiﬁcant when compared with the control group.
Table 4 Postoperative pain score control group (n= 30); DEX group (n= 30); data are in median and interquartile range.
Control group median (IQR) DEX group median (IQR) P value
1 h (ICU) 5(2–7) 2(0–3)* <0.001***
4 h (ICU) 4(3–5) 2(0–5)* <0.001***
8 h (ICU) 4(3–5) 2(0–3)* <0.001***
12 h (ICU) 4(3–5) 2(0–3)* <0.001***
* P< 0.05 signiﬁcant when compared with the control group.
350 G.Z. El-Morsy, A.F. Elgamalactivation of a2-adrenergic receptors in the dorsal horn of the
spinal cord and the inhibition of substance P release [16].In our study we noted that low entropy values and early
extubation time that run in accordance with Easley et al.
Figure 3 Entropy values of the studied groups. * P< 0.05 signiﬁcant when compared with the control group.
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surgery for congenital heart diseases [17]. This Fact may be
contributed to the anesthetic-sparing effect of dexmedetomi-
dine. Aho, Khan and Fragen noted reduction in inhalational
anesthetic requirements for maintenance of anesthesia. In
addition, the use of dexmedetomidine produces intraoperative
and postoperative opioid-sparing effect [18–20]. Early dis-
charge from ICU and hospital is markedly increased in control
group when compared to DEX group in our study. This may
be attributed to low doses of anesthetic drugs that had been
used, low total doses of fentanyl, more hemodynamic stability
and early regain of consciousness.
5. Conclusions
In summary, dexmedetomidine is a short-acting alpha2-adre-
noceptor agonist with many desirable clinical beneﬁts that
encourage its use in the perioperative period. Dexmedetomi-
dine has anesthesia-sparing effects, it decreases MAP, HR
and with reasonable analgesic effect.
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